Long-term outcomes of childhood cancer survivors in Sweden: A population-based study of education, employment, and income

Cancer ◽  
2010 ◽  
Vol 116 (5) ◽  
pp. 1385-1391 ◽  
Author(s):  
Krister K. Boman ◽  
Frank Lindblad ◽  
Anders Hjern
2009 ◽  
Vol 10 (2) ◽  
pp. 134-137 ◽  
Author(s):  
Margarett Shnorhavorian ◽  
Debra L. Friedman ◽  
Martin A. Koyle

2018 ◽  
Vol 42 (5) ◽  
pp. 533-539 ◽  
Author(s):  
Iliana C. Lega ◽  
Jason D. Pole ◽  
Peter C. Austin ◽  
Cindy Lau ◽  
Paul C. Nathan ◽  
...  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 10561-10561
Author(s):  
Ashna Khanna ◽  
Priscila Pequeno ◽  
Sumit Gupta ◽  
Paaladinesh Thavendiranathan ◽  
Husam Abdel-Qadir ◽  
...  

2020 ◽  
Vol 38 (23) ◽  
pp. 2639-2646
Author(s):  
Jason A. Beyea ◽  
Cindy Lau ◽  
Bonnie Cooke ◽  
Stephen Hall ◽  
Paul C. Nathan ◽  
...  

PURPOSE Hearing loss is a significant late effect among childhood cancer survivors. Recent guidelines note insufficient evidence to quantify its natural history or risk associated with specific exposures. We examined the long-term incidence and predictors of hearing loss requiring hearing amplification devices (HADs) using population-based health care data. METHODS In Ontario, Canada, HAD costs are subsidized by the Assistive Devices Program (ADP). Ontario children < 18 years of age at cancer diagnosis between 1987 and 2016 were identified and linked to ADP claims. Cumulative HAD incidence was compared between cases and matched controls. Patient, disease, and treatment predictors of HAD were examined. RESULTS We identified 11,842 cases and 59,210 controls. Cases were at higher risk for HAD (hazard ratio [HR], 12.8; 95% CI, 9.8 to 16.7; P < .001). The cumulative incidence of HAD among survivors was 2.1% (95% CI, 1.7% to 2.5%) at 20 years and 6.4% (95% CI, 2.8% to 12.1%) at 30 years post-diagnosis. The 30-year incidence was highest in neuroblastoma (10.7%; 95% CI, 3.8% to 21.7%) and hepatoblastoma (16.2%; 95% CI, 8.6% to 26.0%) survivors. Predictors of HAD in multivariable analyses included age 0-4 years at diagnosis ( v 5-9 years; HR, 2.2; 95% CI, 1.4-3.3; P < .001). Relative to no cisplatin exposure, patients receiving < 200 mg/m2 were not at greater risk, unlike those receiving higher cumulative doses. Relative to no cranial or facial radiation, those who had received ≤ 32.00 Gy were at no higher risk, unlike those who had received > 32.00 Gy. Carboplatin exposure was not associated with HAD. CONCLUSION Childhood cancer survivors are at elevated risk for requiring HAD, which continues to increase between 20 and 30 years after diagnosis. Thresholds of cisplatin and radiation exposure exist, above which risk substantially increases. Prolonged monitoring and trials of otoprotective agents are warranted in high-risk populations.


2004 ◽  
Vol 74 (6) ◽  
pp. 1282-1285 ◽  
Author(s):  
Jeanette Falck Winther ◽  
John D. Boice ◽  
John J. Mulvihill ◽  
Marilyn Stovall ◽  
Kirsten Frederiksen ◽  
...  

2016 ◽  
Vol 64 ◽  
pp. 52-61 ◽  
Author(s):  
Trine Gade Bonnesen ◽  
Jeanette F. Winther ◽  
Peter H. Asdahl ◽  
Sofie de Fine Licht ◽  
Thorgerdur Gudmundsdottir ◽  
...  

PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0232708
Author(s):  
Nina Streefkerk ◽  
Wim J. E. Tissing ◽  
Joke C. Korevaar ◽  
Eline van Dulmen-den Broeder ◽  
Dorine Bresters ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document